Take This Into Account Before Investing in LLY

By Ken Smith • Thursday, October 23 15:19 • Permanent Link

Large-cap Health Care company Eli Lilly and has moved 1.2% so far today on a volume of 1,647,326, compared to its average of 4,587,495. In contrast, the S&P 500 index moved 1.0%.

Eli Lilly and trades -8.47% away from its average analyst target price of $898.04 per share. The 27 analysts following the stock have set target prices ranging from $650.0 to $1190.0, and on average have given Eli Lilly and a rating of buy.

If you are considering an investment in LLY, you'll want to know the following:

Eli Lilly and's current price is 1178.1% above its Graham number of $64.31, which implies that at its current valuation it does not offer a margin of safety
Eli Lilly and has moved -8.9% over the last year, and the S&P 500 logged a change of 15.3%
Based on its trailing earnings per share of 15.27, Eli Lilly and has a trailing 12 month Price to Earnings (P/E) ratio of 53.8 while the S&P 500 average is 29.3
LLY has a forward P/E ratio of 36.3 based on its forward 12 month price to earnings (EPS) of $22.66 per share
Its Price to Book (P/B) ratio is 40.34 compared to its sector average of 3.19
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally.
Based in Indianapolis, the company has 47,000 full time employees and a market cap of $736.84 Billion. Eli Lilly and currently returns an annual dividend yield of 0.7%.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.